Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2005

View Archived Issues

GRN-163L suppresses human hepatoma growth in mice

Anticocaine antibody prevents death in a model of cocaine overdose

Eight-day oseltamivir dosing more effective than five-day against H5N1 influenza virus in mice

Farnesyltransferase inhibitors show promise for treating progeria

Nanobodies may substitute monoclonal antibodies

AVE-7688 reduces renal fibrosis in COL4A3-/- mice

AlphaRx completes development of vancomycin delivered with nanoparticle delivery platform

Alnylam Pharmaceuticals updates product pipeline

Xoma signs manufacture agreement for Cubist's HepeX-B biologic

Kereos raises funds to support clinical evaluation of MRI agents and therapeutics

Vion initiates solid tumor clinical development program with Cloretazine

Beta-2 adrenergic agonist carmoterol interacts positively with budesonide and tiotropium

Survival benefits of MEDI-522 in advanced melanoma patients

Ruboxistaurin improves renal function in patients with type 2 diabetes and nephropathy

Phase II data on rEV-131 in seasonal allergic rhinitis

Vyteris' Actyve transdermal drug delivery technology shows promise in phase I

Genaissance and Otsuka enter genetic markers research alliance

GSK's Zefix approved in Japan for HBV-associated cirrhosis

XTLbio licenses anti-HCV compounds and technology from VivoQuest

New therapeutic agents disclosed for respiratory disorders

Tripep advances alpha-HGA to phase I/II trial for HIV

Recent patents cover novel treatments for neurological disorders

Cipralex receives European approval for generalized anxiety disorder

Triglyceride reducing agents emerge from Esteve R&D

Studies reveal efficacy of Lanreotide Autogel in acromegaly patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...